Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.

Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects against EGFR mutant lung cancer, patients ultimately develop resistance by multiple mechanisms. We therefore assessed the ability of combined treatment with the Met inhibitor crizotinib and new generation EGFR-TK...

Full description

Bibliographic Details
Main Authors: Shigeki Nanjo, Tadaaki Yamada, Hiroshi Nishihara, Shinji Takeuchi, Takako Sano, Takayuki Nakagawa, Daisuke Ishikawa, Lu Zhao, Hiromichi Ebi, Kazuo Yasumoto, Kunio Matsumoto, Seiji Yano
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3873434?pdf=render

Internet

http://europepmc.org/articles/PMC3873434?pdf=render

Similar Items